Biliary Tract Cancer
Conditions
Keywords
Adebrelimab, Hepatic Arterial Infusion Chemotherapy, Lenvatinib, Potentially Resectable Biliary Tract Cancer
Brief summary
This is a single-arm, exploratory, phase II trial to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy combined with adebrelimab and lenvatinib for borderline resectable, locally advanced biliary tract cancer.
Detailed description
This study plans to recruit 30 patients with borderline resectable, locally advanced biliary tract cancer who have not received treatment， abserve and evaluate the efficacy and safety of hepatic arterial infusion chemotherapy combined with adebrelimab and lenvatinib.
Interventions
DRUGAdebrelimab
Adebrelimab, IV
DRUGLenvatinib
Lenvatinib, PO
GC regimen±5-FU
Sponsors
Harbin Medical University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Age: 18 to 75 years old, male or female; 2. Biliary tract malignant tumors confirmed by histology or cytology, with measurable tumor lesions (spiral CT or MR scan ≥10mm, meeting RECIST 1.1 standards); 3. Borderline resectable, locally advanced biliary malignant tumors, including gallbladder cancer, intrahepatic cholangiocarcinoma, hilar cholangiocarcinoma, and distal cholangiocarcinoma; 4. Clinical stage: gallbladder cancer stage: IIIA-IVB; intrahepatic cholangiocarcinoma stage: IIA-IV; hilar cholangiocarcinoma stage: IIIB-IVB; distal cholangiocarcinoma stage: IIIA-IV; 5. Expected survival \> 3 months; 6. ECOG PS score: 0-1 points; 7. Liver function classification is Child-Pugh ≤7; 8. Never received prior systemic treatment for biliary tract tumors; 9. No peritoneal metastasis or other distant metastasis; 10. Normal function of major organs; 11. Women of childbearing age must have a negative pregnancy test (βHCG) before starting treatment, and women of childbearing potential and men (who have sexual active with women of childbearing potential) must agree to effective contraception uninterrupted for the duration of the treatment and for 6 months after the last therapeutic dose; 12. Patients voluntarily enrolled in the study by signing an informed consent form.
Exclusion criteria
1. Patients diagnosed with periampullary cancer; 2. Previous or concurrent other malignant tumours within 5 years, except cervical carcinoma in situ, cutaneous squamous cell carcinoma or basal cell carcinoma of the skin that has been basically controlled; 3. Those with uncontrolled, symptomatic brain metastases or a history of uncontrollable mental illness or severe intellectual or cognitive dysfunction; 4. Pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia and severely impaired lung function; 5. Suffering from active autoimmune diseases, history of autoimmune diseases, such as interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism; Reduced thyroid function after thyroid hormone replacement therapy can be included; 6. Have a history of immunodeficiency, including testing positive for HIV, suffering from other acquired or congenital immunodeficiency diseases, or a history of organ transplantation and allogeneic bone marrow transplantation; 7. Subjects have cardiovascular clinical symptoms or diseases that cannot be well controlled, including but not limited to: 1) NYHA class II or above heart failure; 2) Unstable angina; 3) Myocardial infarction within 1 year; 4) Clinically significant supraventricular or ventricular arrhythmia requiring clinical intervention; 8. Severe active infection requiring intravenous antibiotic treatment occurs during the screening period; 9. Those who are allergic to experimental drugs; 10. Patients who cannot comply with the trial protocol or cannot cooperate with follow-up visits; 11. Those who the researcher believes are not suitable to participate in this trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| R0 resection rate | up to 24 months | Postoperative staining results showed that the lesion was completely resected, and pathological biopsy of the transverse and longitudinal margins were negative. |
| Surgery conversion rate | up to 24 months | Proportion of patients who can undergo surgical resection among all enrolled patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Major pathological response rate | up to 24 months | After preoperative treatment and surgery, the proportion of residual viable tumor cells in the tumor bed in the postoperative specimen is less than or equal to 10% (%RVT≤10)\* |
| Recurrence-free survival | up to 24 months | Duration from surgical resection to first recurrence or death from any cause |
| Objective response rate | up to 24 months | The proportion of patients whose tumor volume shrinks to a predetermined value and can maintain the minimum time limit, which is the sum of the proportions of complete remission and partial remission. |
| AEs | up to 24 months | Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0. |
| Overall survival | up to 24 months | Overall survival is measured from the first dose of study drug until death from any cause. |
| pathological complete response rate | up to 24 months | After preoperative treatment and surgery, there are no residual viable tumor cells in the tumor bed in the postoperative specimen (%RVT=0) |
Contacts
Primary ContactYubao Zhang, MD
Outcome results
None listed